ALXN
$123.83
Alexion Pharm
$.90
.73%
ALXN
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  $2.25
Revenue:  $1.44 Bil
Thursday
Jan 28
6:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Thursday, October 29, 2020

What do you expect when ALXN reports earnings?
Beat
Meet
Miss

Where is ALXN's stock price going from here?
Up
Flat
Down
Stock chart of ALXN
Analysts
Summary of analysts' recommendations for ALXN
Score
Grade
Pivots
Resistance
$126.47
$125.24
$124.53

$123.30

Support
$122.59
$121.36
$120.65
Tweet
Growth
Description
Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).
Peers
IncyteExact SciencesCharles River Laboratories InternationalExelixisCoherus BiosciencesLuminex